Growth factors for therapeutic angiogenesis in Cardiovascular diseases

Revista Espanola de Cardiologia

Volumn 54, Issue 10, 2001, Pages 1210-1224

  Vale, Peter R ^a   Losordo, Douglas W ^a   Symes, James F ^a   Isner, Jeffrey M ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

FGF; Gene transfer; Myocardial ischemia; Peripheral arterial disease; VEGF

Indexed keywords

CYTOKINE; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; RECOMBINANT PROTEIN; VASCULOTROPIN; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY DISEASE; ARTERY OCCLUSION; ARTICLE; CARDIOVASCULAR DISEASE; CLASSIFICATION; CLINICAL TRIAL; COLLATERAL CIRCULATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY SURGERY; DRUG EFFICACY; DRUG SAFETY; DRUG TOXICITY; EVIDENCE BASED MEDICINE; FEASIBILITY STUDY; GENE THERAPY; GENETIC CODE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; NONHUMAN; PAIN; SIDE EFFECT; TISSUE PERFUSION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT FAILURE; TREATMENT INDICATION; DRUG SCREENING; GENETICS; ISCHEMIA; LEG; METHODOLOGY; PERIPHERAL VASCULAR DISEASE; RECURRENT DISEASE; VASCULARIZATION;

CLINICAL TRIALS; DRUG EVALUATION; ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTORS; GENE THERAPY; HUMANS; ISCHEMIA; LEG; LYMPHOKINES; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL VASCULAR DISEASES; RECURRENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034746776     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-8932(01)76480-9     Document Type: Article

References (109)

1. Tumor angiogenesis: Therapeutic implications
2. Differentiation of endothelium
3. Angiogenesis
4. Mechanisms of angiogenesis
5. Isolation of putative progenitor endothelial cells for angiogenesis
6. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization
7. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
8. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic
9. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb
10. Hypoxia-induced paracrine regulation of VEGF receptor expression
11. Role of flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
12. Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice
13. Molecular analysis of blood vessel formation and disease
14. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
15. Vascular endothelial growth factor is a secreted angiogenic mitogen
16. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
17. Purification of glycoprotein vascular endothelial cell mitogen from a rat glioma cell line
18. Vascular endothelial growth factor165 gene transfer augments circulating endothelial progenitor cells in human subjects
19. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells
20. Mobilization of endothelial progenitor cells following gene therapy with VEGF165 in patients with inoperable coronary disease
21. Mechanisms of angiogenesis and arteriogenesis
22. Arterial gene transfer of acidic fibroblast growth factor for therapeutic angiogenesis in vivo: Critical role of secretion signal in use of naked DNA
23. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart
24. Intracoronary gene transfer of fibroblast growth factor-4 increases regional contractile function and responsiveness to adrenergic stimulation in heart failure
25. Increased expression of direct gene transfer into skeletal muscles observed after acute ischemic injury in rats
26. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion
27. Time course of recombinant protein secretion following liposome-mediated gene transfer in a rabbit arterial organ culture model
28. Use of the rabbit ear artery to serially assess foreign protein secretion after site specific arterial gene transfer in vivo: Evidence that potential magnitude of transgene expression
29. Second European consensus document on chronic critical leg ischemia
30. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis
31. Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon
32. Therapeutic angiogenesis: A single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hindlimb model
33. Clinical evidence of angiogenesis following arterial gene transfer of phVEGF165
34. Low-efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit
35. Rescue of diabetes related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF
36. Constitutive expression of phVEGF165 following intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
37. Age < 50 years and rest pain predict positive clinical outcome after intramuscular gene transfer of phVEGF165 in patients with critical limb ischemia
38. Lower-extremity edema associated with gene transfer of naked DNA vascular endothelial growth factor
39. Treatment of thromboangiitis obliterans (Buerger’s disease) by intramuscular gene transfer of vascular endothelial growth factor: Preliminary clinical results
40. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia
41. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: Dose-response effect of basic fibroblast growth factor
42. Basic fibroblast growth factor increases collateral blood flow in rats with femoral artery ligation
43. Basic FGF enhances the development of collateral circulation after acute arterial occlusion
44. Basic fibroblast growth factor in patients with intermittent claudication: Results of a phase I trial
45. Tissue and myocardial distribution of intracoronary, intravenous, intrapericardial and intramyocardial 125I-labeled basic fibroblast growth factor (bFGF) favor intramyocardial delivery
46. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts
47. VEGF administration in chronic myocardial ischemia in pigs
48. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs
49. Intramyocardial but not intravenous vascular endothelial growth factor improves regional perfusion in hibernating porcine myocardium
50. Vascular endothelial growth factor in chronic myocardial ischemia
51. Catheter-based gene transfer of VEGF utilizing electromechanical LV mapping accomplishes therapeutic angiogenesis: Pre-clinical studies in swine
52. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium
53. Percutaneous electromechanical mapping demonstrates efficacy of pVGI.1 (VEGF2) in an animal model of chronic myocardial ischemia
54. Biologic bypass with the use of adenovirus-mediated gene transfer of the conplementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart
55. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endotehlial growth factor 121
56. Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: Effect on myocardial angiogenesis
57. Catheter-based myocardial gene transfer utilizing non-fluoroscopic electromechanical left ventricular mapping
58. Percutaneous endocardial gene therapy: Patterns of in-vivo gene expression related to regional myocardial delivery
59. Catheter-based transendocardial injection of adenoviral VEGF121 offers equivalent gene delivery and protein expression compared to a surgical-based transepicardial injection approach
60. Basic fibroblast growth factor enhances myocardial collateral flow in a canine
61. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart
62. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and arterial response to injury
63. Intracoronary basic fibroblast growth factor enhances myocardial collateral perfusion in dogs
64. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts
65. Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: A comparison of angiographic, echocardiographic and coronary flow parameters
66. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia
67. Effects of acidic fibroblast growth factor on normal and ischemic myocardium
68. Extracardiac to coronary anastomoses support regional left ventricular function in dogs
69. Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia
70. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: Preliminary clinical results
71. Intraoperative multiplane transesophageal echocardiograpy for guiding direct myocardial gene transfer of vascular endothelial growth factor in patients with refractory angina pectoris
72. Mechanism of impaired myocardial function during progressive coronary stenosis in conscious pigs: Hibernation versus stunning?
73. Hibernating myocardium
74. Current diagnostic techniques of assessing myocardial viability in patients with hibernating and stunned myocardium
75. Left ventricular electromechanical mapping to assess efficacy of phVEGF165 gene transfer for therapeutic angiogenesis in chronic myocardial ischemia
76. Methods of local gene delivery to vascular tissues
77. Electromagnetic guidance for catheter-based transendocardial injection: A platform for intramyocardial angiogenesis therapy
78. Randomized, placebo-controlled clinical study of percutaneous catheter-based left ventricular endocardial gene transfer of VEGF-2 for myocardial angiogenesis in patients with chronic myocardial ischemia
79. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase 1 randomized, double-blind, placebo-controlled trial
80. First angiogenic treatment of coronary heart disease by FGF-1: Long-term results after 3 years
81. Induction of myocardial neoangiogenesis by human growth factors. A new therapeutic option in coronary heart disease
82. Results of intracoronary recombinant human vascular endothelial growth factor (rhVEGF) administration trial
83. Final results of the VIVA trial of rhVEGF for human therapeutic angiogenesis
84. Meeting highlights: Highlights of the 48th scientific sessions of the american college of cardiology
85. VIVA trial: One year follow up
86. Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000
87. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery
88. Accelerated restitution of endothelial integrity and endothelium-dependent function following phVEGF165 gene transfer
89. Stent endothelialization: Time course, impact of local catheter delivery, feasibility of recombinant protein administration, and response to cytokine expedition
90. Passivation of metallic stents following arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening
91. VEGF gene delivery to muscle: Potential role of vasculogenesis in adults
92. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat: Angiogenesis and angioma formation
93. Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders
94. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1
95. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension
96. Vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) augments nitric oxide release from quiescent rabbit and human vascular endothelium
97. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia
98. A double-blind, placebo-controlled, phase II study of basic fibroblast growth factor in the treatment of intermittent claudication
99. Angiogenesis inhibitors endostatin and TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice
100. Arterial gene therapy for inhibiting restenosis in patients with claudication undergoing superficial femoral artery angioplasty
101. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty
102. Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo
103. Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia
104. Influence of vascular endothelial growth factor on diabetic retinopathy
105. Transmyocardial laser revascularisation in patients with refractory angina: A randomised controlled trial
106. Transmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: A prospective randomised trial
107. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina
108. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease
109. 2 laser in patients with refractory angina pectoris: Clinical results from the Norwegian randomized trial